A carregar...
MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
Acute myeloid leukemia (AML) is a clonal heterogenous malignancy of the myeloid cells with a poor prognosis lending itself to novel treatment strategies. TP53 is a critical tumor suppressor and plays an essential role in leukemogenesis. Although TP53 is relatively unusual in de novo AML, inactivatio...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6563714/ https://ncbi.nlm.nih.gov/pubmed/31289443 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S172315 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|